Apoptosis and Its Relevance to Autoimmunity

Editor(s): Elkon K.B. (Seattle, Wash.) 
Table of Contents
Vol. 9, No. , 2006
Section title: Paper
Elkon K (ed): Apoptosis and Its Relevance to Autoimmunity. Curr Dir Autoimmun. Basel, Karger, 2006, vol 9, pp 173-187

Clearance of Apoptotic Cells in Human SLE

Gaipl U.a · Kuhn A.b · Sheriff A.a · Munoz L.a · Franz S.a · Voll R.c · Kalden J.a · Herrmann M.a
aInstitute for Clinical Immunology, Department of Medicine III, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, bDepartment of Dermatology, University of Düsseldorf, Düsseldorf, and cIZKF Research Group 2, Nikolaus-Fiebiger Center of Molecular Medicine, Erlangen, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.


Systemic lupus erythematosus (SLE) is characterized by a diverse array of autoantibodies, particularly against nuclear antigens, thought to derive from apoptotic and necrotic cells. Impaired clearance functions for dying cells may explain accumulation of apoptotic cells in SLE tissues, and secondary necrosis of these cells may contribute to the chronic inflammation in this disease. The exposure of phosphatidylserine (PS) and altered carbohydrates on dying cells are important recognition signals for macrophages. Furthermore, serum factors such as complement, DNase I, pentraxins (e.g. C-reactive protein) and IgM contribute to efficient opsonization and uptake of apoptotic and necrotic cells. Defects in these factors may impact the development of SLE in humans and mice in a variety of ways. We observed impaired clearance of apoptotic cells in lymph nodes and skin biopsies of humans with lupus, as well as intrinsic defects of macrophages differentiated in vitro from SLE patients’ CD34+ stem cells, demonstrating that apoptotic cells are not properly cleared in a subgroup of patients with SLE. This altered mechanism for the clearance of dying cells may represent a central pathogenic process in the development and acceleration of this autoimmune disease.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: 1/3/2006
Cover Date: 2006

Number of Print Pages: 15
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-8036-6 (Print)
eISBN: 978-3-318-01294-1 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.